PATENT CLAIM ANALYSIS

Application Number: 16072638
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["424", "133100"]

Abstract:
The present invention relates to liquid pharmaceutical compositions of a VEGF antagonist for intravitreal administration comprising a histidine buffer, an inorganic salt, a carbohydrate and a polysorbate.

Claim (Index 16):
The method of  claim 1 , wherein the intraocular neovascular disease is age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema (DME), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), or visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 95.0
- Lexical Diversity: 1.15385
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15037254', '15190378', '16305987', '14934666', '15623684']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7059493227349453
- 35 USC 102 Novelty (BERT): 0.530835717632499
- Combined Prediction Score: 0.6884379622247006
- Mean Citation Score: 266.262532
- Max Citation Score: 345.1267
- Similarity Product: 226.96561909834148

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test